Cleared Traditional

TELAVANCIN 30 UG, BBL SENSI-DISC (K100722) - FDA 510(k) Clearance

Class II Microbiology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K100722 · Becton, Dickinson and Company · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2010
Decision
14d
Days
Class 2
Risk

K100722 is an FDA 510(k) clearance for the TELAVANCIN 30 UG, BBL SENSI-DISC. Classified as Susceptibility Test Discs, Antimicrobial (product code JTN), Class II - Special Controls.

Submitted by Becton, Dickinson and Company (Sparks, US). The FDA issued a Cleared decision on March 29, 2010 after a review of 14 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.1620 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Becton, Dickinson and Company devices

Submission Details

510(k) Number K100722 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 15, 2010
Decision Date March 29, 2010
Days to Decision 14 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
88d faster than avg
Panel avg: 102d · This submission: 14d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JTN Susceptibility Test Discs, Antimicrobial
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.1620
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - JTN Susceptibility Test Discs, Antimicrobial

All 99
Devices cleared under the same product code (JTN) and FDA review panel - the closest regulatory comparables to K100722.
HardyDisk AST Delafloxacin 5 µg (DLX5)
K171975 · Hardy Diagnostics · Aug 2017
HardyDisk Ceftolozane/Tazobactam, (30/10 ug)-C/T40
K170127 · Hardy Diagnostics · Mar 2017
BD BBL Sensi-Disc Ceftazidime Avibactam (30/20ug), Antimicrobial Susceptibility Test Disks
K152516 · Becton, Dickinson and Company · Oct 2015
FLUCONAZOLE 25UG BBL SENSI-DISC
K082271 · Becton, Dickinson & CO · Oct 2008
VORICONAZOLE 1UG BBL SENSI-DISC
K082272 · Becton, Dickinson & CO · Oct 2008
DORIPENEM 10UG BBL SENSI-DISC
K080998 · Becton, Dickinson & CO · May 2008